What do systematic reviews say?

5 questions · 5 findings · 1 reviews · HIV/AIDS

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 0 · 0%Moderate 4 · 80%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- HAART + ABV vs HAART alone · Clinical response ‐ partial response
  Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
  RR 1.71 [1.01, 2.91]
  1 study · 100 participants
  Moderate
Direct match · question page
- Liposomal daunorubicin vs ABV · Clinical response ‐ partial response
  Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
  RR 0.83 [0.53, 1.31]
  1 study · 227 participants
  Moderate
Direct match · question page
- Bleomycin vs ABV · Clinical response ‐ partial response
  Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
  RR 0.11 [0.01, 1.86]
  1 study · 24 participants
  Very low
Direct match · question page
- HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin · Clinical response ‐ partial response
  Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
  RR 1.04 [0.5, 2.17]
  1 study · 49 participants
  Moderate
Related · question page
- HAART + ABV vs HAART alone · Clinical response ‐ overall response (complete and partial)
  Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
  RR 1.78 [1.16, 2.72]
  1 study · 100 participants
  Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ partial response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.04 [0.5, 2.17]
1 study · 49 participants
Moderate

Liposomal daunorubicin vs ABV

Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

Liposomal daunorubicin showed no clear difference in clinical response ‐ partial response compared with ABV (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.83 [0.53, 1.31]
1 study · 227 participants
Moderate

Bleomycin vs ABV

Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

It is very uncertain whether bleomycin changes clinical response ‐ partial response compared with ABV (very low certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.11 [0.01, 1.86]
1 study · 24 participants
Very low

HAART + ABV vs HAART alone

Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV probably leads to higher clinical response ‐ partial response compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.71 [1.01, 2.91]
1 study · 100 participants
Moderate

HAART + ABV vs HAART alone

Complete or partial remission · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV probably leads to higher clinical response ‐ overall response (complete and partial) compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.78 [1.16, 2.72]
1 study · 100 participants
Moderate